Do You Need an LPPV in the Nordic Countries?

While the Nordic countries are often viewed as a single region, pharmacovigilance (PV) requirements and local expectations can vary from country to country. Understanding where local representation is required, and where it remains optional, is essential for Marketing Authorization Holders (MAHs) seeking to maintain compliance while ensuring the effective management of safety activities across the region.

Despite this regional approach, national competent authorities may have country-specific expectations for local PV support. As a result, MAHs must consider not only their regulatory obligations but also the practical benefits of maintaining local PV expertise.

Regulatory Overview

PV requirements within the European Economic Area (EEA) are largely harmonized through the framework established by the European Medicines Agency (EMA). A key component of this framework is the requirement for a Qualified Person for Pharmacovigilance (QPPV) at the EU level. They are responsible for maintaining and overseeing the PV system of an MAH. MAHs are required to appoint a QPPV in accordance with the following:

• Article 23 of Regulation (EC) No 726/2004
• Article 103 of Directive 2001/83/EC, as amended by Regulation (EU) No 1235/2010 and Directive 2010/84/EU

In addition to the EU-QPPV, some countries may impose national requirements, such as the appointment of a Local Person for Pharmacovigilance (LPPV) or a local contact person. However, within the Nordic region such requirements are limited or not mandatory, with national authorities retaining the option to request local representation when deemed necessary.

The requirements for the LPPV in the European countries are outlined in "Information on the Member States Requirement for the Nomination of a Pharmacovigilance (PhV) Contact Person at National Level – Human Medicines Requirements (EMA/INS/PhV/129721/2024, Rev. 5, 13 August 2025)".

The current requirements for the Nordic countries are summarized below.

Pharmacovigilance Contact Requirements in the Nordic Countries

Denmark

Not mandatory. According to national legislation (Medicines Act § 53), the Danish Medicines Agency (DKMA) may require the MAH of a medicinal product for human use to nominate a contact person in Denmark to represent the EU-QPPV. Up until now, this has not yet been imposed on MAHs.

Finland

Not mandatory. Under the Finnish Medicines Act (Medicines Act 30 c §), the Finnish Medicines Agency (Fimea) may request the nomination of a PV contact person at national level. Fimea recommends that the MAH nominate such a contact person for PV issues. The contact person does not need to hold a specific medical degree, but a good knowledge of PV practices and regulatory requirements is beneficial. If no contact person is nominated, all individual case safety report (ICSR) communication will be directed to the EU QPPV.

Iceland

Not mandatory. Icelandic Regulation No. 545/2018 requires the appointment of an EU-QPPV, but does not require a local PV contact person.

Norway

Not mandatory. There are currently no national requirements to designate a PV contact person for human medicinal products.

Sweden

Not mandatory. There is no national requirement for the nomination of a local PV contact person.

Why Local Pharmacovigilance Expertise Still Matters in the Nordics

Although the Nordic countries operate under the shared PV framework of the EMA, they do not currently impose mandatory requirements for a LPPV. However, national competent authorities may recommend or reserve the right to request a local contact person, particularly to facilitate communication and ensure efficient handling of safety information at the national level.

Key Responsibilities of a Local PV Contact

While not legally required, having a local contact person in the Nordics is essential to ensure proper understanding and handling of the following:

• Direct communication with national authorities and healthcare professionals: Act as a local point of contact and communicate in the local language.
• Local literature monitoring: Develop and implement search strategies to identify relevant publications in local journals and databases.
• Regulatory intelligence: Monitor and review official regulatory authority websites for new requirements, guidance updates, and emerging regulatory developments.
• PV training: Deliver PV training to local teams, distributors, and external vendors.
• Local PV processes: Establish and maintain country-specific PV procedures that align with local expectations and global systems.
• Safety data management: Support the collection, review, and handling of incoming safety information in accordance with local procedures and reporting requirements.

Conclusion

While Denmark, Finland, Iceland, Norway, and Sweden do not currently require MAHs to appoint a LPPV, regulatory compliance extends beyond meeting minimum legal obligations. Effective PV relies on clear communication, awareness of local regulatory developments, and the ability to respond promptly to country-specific requirements.

Maintaining local PV expertise in the Nordic region can strengthen support for the EU-QPPV, improve engagement with national authorities and healthcare professionals, and help ensure the consistent implementation of PV activities across markets. As regulatory expectations continue to evolve, a knowledgeable local presence can provide valuable insight, enhance operational efficiency, and help organizations remain inspection-ready while protecting patient safety.